Search Results - "Lydon, Christine A."

Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer by Bahcall, Magda, Sim, Taebo, Paweletz, Cloud P, Patel, Jyoti D, Alden, Ryan S, Kuang, Yanan, Sacher, Adrian G, Kim, Nam Doo, Lydon, Christine A, Awad, Mark M, Jaklitsch, Michael T, Sholl, Lynette M, Jänne, Pasi A, Oxnard, Geoffrey R

“…Amplified and/or mutated MET can act as both a primary oncogenic driver and as a promoter of tyrosine kinase inhibitor (TKI) resistance in non-small cell lung…”
Get more information

Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome by Araki, Tetsuro, Dahlberg, Suzanne E, Hida, Tomoyuki, Lydon, Christine A, Rabin, Michael S, Hatabu, Hiroto, Johnson, Bruce E, Nishino, Mizuki

“…Highlights • The presence of baseline interstitial lung abnormalities (ILA) in patients with advanced non-small-cell lung cancer (NSCLC) is significantly…”
Get full text

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs by Lin, Jessica J, Cardarella, Stephanie, Lydon, Christine A, Dahlberg, Suzanne E, Jackman, David M, Jänne, Pasi A, Johnson, Bruce E

“…Activating mutations in the epidermal growth factor receptor gene (EGFR) predict for prolonged progression-free survival in patients with advanced non-small…”
Get more information

Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib by Nishino, Mizuki, Hida, Tomoyuki, Kravets, Sasha, Dahlberg, Suzanne E., Lydon, Christine A., Hatabu, Hiroto, Johnson, Bruce E., Awad, Mark M.

“…•Tumor growth rate of ALK-rearranged NSCLC treated with crizotinib was assessed.•Overall growth rate after nadir was 0.04/month for the logarithm of tumor…”
Get full text

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma by Vokes, Natalie I, Chambers, Emily, Nguyen, Tom, Coolidge, Alexis, Lydon, Christine A, Le, Xiuning, Sholl, Lynette, Heymach, John V, Nishino, Mizuki, Van Allen, Eliezer M, Jänne, Pasi A

“…Patients with EGFR-mutant NSCLC experience variable duration of benefit on EGFR tyrosine kinase inhibitors. The effect of concurrent genomic alterations on…”
Get more information

The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute by Tolaney, Sara M, Lydon, Christine A, Li, Tianyu, Dai, Jiale, Standring, Andrea, Legor, Kristen A, Caparrotta, Caryn M, Schenker, Matthew P, Glazer, Daniel I, Tayob, Nabihah, DuBois, Steven G, Meyerhardt, Jeffrey A, Taplin, Mary-Ellen, Johnson, Bruce E

“…Abstract Interventions designed to limit the spread of coronavirus disease 2019 (COVID-19) are having profound effects on the delivery of health care, but data…”
Get full text

Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome by Nishino, Mizuki, Dahlberg, Suzanne E, Adeni, Anika E, Lydon, Christine A, Hatabu, Hiroto, Jänne, Pasi A, Hodi, F Stephen, Awad, Mark M

“…We evaluated tumor burden dynamics in patients with advanced non-small cell lung cancer (NSCLC) treated with commercial PD-1 inhibitors to identify imaging…”
Get full text

Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer by Ostios-Garcia, Lorena, Faig, Jennifer, Leonardi, Giulia C, Adeni, Anika E, Subegdjo, Safiya J, Lydon, Christine A, Rangachari, Deepa, Huberman, Mark S, Sehgal, Kartik, Shea, Meghan, VanderLaan, Paul A, Cheng, Matthew P, Marty, Francisco M, Hammond, Sarah P, Costa, Daniel B, Awad, Mark M

“…Despite widespread administration of programmed death receptor 1 (PD-1) pathway inhibitors among individuals with NSCLC, little is known about the safety and…”
Get more information

M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome by Park, Hyesun, Dahlberg, Suzanne E., Lydon, Christine A., Araki, Tetsuro, Hatabu, Hiroto, Rabin, Michael S., Johnson, Bruce E., Nishino, Mizuki

“…Background The 8th edition of TNM staging of non‐small cell lung cancer (NSCLC) has revised M classification and defined M1b disease with single extrathoracic…”
Get full text

Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study by Ghazani, Arezou A., Oliver, Nelly M., St. Pierre, Joseph P., Garofalo, Andrea, Rainville, Irene R., Hiller, Elaine, Treacy, Daniel J., Rojas-Rudilla, Vanesa, Wood, Sam, Bair, Elizabeth, Parello, Michael, Huang, Franklin, Giannakis, Marios, Wilson, Frederick H., Stover, Elizabeth H., Corsello, Steven M., Nguyen, Tom, Rana, Huma Q., Church, Alanna J., Lowenstein, Carol, Cibulskis, Carrie, Amin-Mansour, Ali, Heng, Jennifer, Brais, Lauren, Santos, Abigail, Bauer, Patrick, Waldron, Amanda, Lo, Peter, Gorman, Megan, Lydon, Christine A., Welch, Marisa, McNamara, Philip, Gabriel, Stacey, Sholl, Lynette M., Lindeman, Neal I., Garber, Judy E., Joffe, Steven, Van Allen, Eliezer M., Gray, Stacy W., Jänne, Pasi A., Garraway, Levi A., Wagle, Nikhil

“…Purpose: Implementing cancer precision medicine in the clinic requires assessing the therapeutic relevance of genomic alterations. A main challenge is the…”
Get full text

Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase–rearranged Advanced Non–Small Cell Lung Cancer Patients Treated With Crizotinib by Hida, Tomoyuki, Dahlberg, Suzanne E, Lydon, Christine A, Hatabu, Hiroto, Johnson, Bruce E, Awad, Mark M, Nishino, Mizuki

“…PURPOSE:Targeted inhibition of anaplastic lymphoma kinase (ALK) has been widely used for the treatment of advanced non–small cell lung cancer (NSCLC) with ALK…”
Get full text

Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer by Awad, Mark M, Mastini, Cristina, Blasco, Rafael B, Mologni, Luca, Voena, Claudia, Mussolin, Lara, Mach, Stacy L, Adeni, Anika E, Lydon, Christine A, Sholl, Lynette M, Jänne, Pasi A, Chiarle, Roberto

“…The anaplastic lymphoma kinase (ALK) is recognized by the immune system as a tumor antigen, and preclinical evidence suggests that ALK-rearranged NSCLCs can…”
Get full text

Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer by Jackman, David M, Zhang, Yichen, Dalby, Carole, Nguyen, Tom, Nagle, Julia, Lydon, Christine A, Rabin, Michael S, McNiff, Kristen K, Fraile, Belen, Jacobson, Joseph O

“…Increasing costs and medical complexity are significant challenges in modern oncology. We explored the use of clinical pathways to support clinical decision…”
Get full text

Comparison of outcomes with PD-L1 tumor proportion score (TPS) of 50-74% vs 75-100% in patients with non-small cell lung cancer (NSCLC) treated with first-line PD-1 inhibitors by Jimenez Aguilar, Elizabeth, Rizvi, Hira, Kravets, Sasha, Lydon, Christine A., Adeni, Anika E., Subegdjo, Safiya, Hellmann, Matthew David, Awad, Mark M.

“…Abstract only…”
Get full text

Genomic complexity in KRAS mutant non-small cell lung cancer (NSCLC) from never/light-smokers v smokers by Redig, Amanda J., Chambers, Emily S., Lydon, Christine A., Dahlberg, Suzanne Eleanor, Alden, Ryan S., Janne, Pasi A.

“…Abstract only…”
Get full text

Tumor response dynamics of advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with commercial PD-1 inhibitors in the clinical setting by Nishino, Mizuki, Dahlberg, Suzanne Eleanor, Adeni, Anika E, Lydon, Christine A., Hatabu, Hiroto, Janne, Pasi A., Hodi, F. Stephen, Awad, Mark M.

“…Abstract only 9087 Background: PD-1 inhibitors have shown promising activity in advanced NSCLC, with increasing clinical use. We evaluated tumor burden…”
Get full text

Cost and survival analysis before and after implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer by Zhang, Yichen, Fraile, Belen, Dalby, Carole Kathleen, Nguyen, Tom, Nagle, Julia, Lydon, Christine A., Rabin, Michael S., McNiff, Kristen K., Jacobson, Joseph O., Jackman, David Michael

“…Abstract only 3 Background: Oncologists face challenges associated with increasing cost and medical complexity. The Dana-Farber Cancer Institute (DFCI) has…”
Get full text

Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression by Gainor, Justin F., Rizvi, Hira, Jimenez Aguilar, Elizabeth, Mooradian, Meghan, Lydon, Christine A., Anderson, Danyon, Tenet, Megan, Sauter, Jennifer L., Mino-Kenudson, Mari, Shaw, Alice Tsang, Awad, Mark M., Hellmann, Matthew David

“…Abstract only…”
Get full text

BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation by Dagogo-Jack, Ibiayi, Martinez, Pablo, Yeap, Beow Y, Ambrogio, Chiara, Lydon, Christine A., Nguyen, Tom, Iafrate, A. John, Lennerz, Jochen K, Johnson, Bruce E., Shaw, Alice Tsang, Awad, Mark M.

“…Abstract only…”
Get full text

Clinical predictors of 5-year survival in patients with EGFR-mutant metastatic NSCLC treated with EGFR-TKIs by Lin, Jessica Jiyeong, Cardarella, Stephanie, Lydon, Christine A., Dahlberg, Suzanne Eleanor, Jackman, David Michael, Janne, Pasi A., Johnson, Bruce E.

“…Abstract only…”
Get full text